Biomarker assessment in bladder cancer V1.0
Research type
Research Study
Full title
Assessment of metabolic biomarkers in archival formalin fixed paraffin embedded (FFPE) sections from bladder tissue.
IRAS ID
189949
Contact name
Claire Perks
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
1 years, 11 months, 26 days
Research summary
Bladder cancer is the 4th most common in cancer in males and 13th in women with a lifetime risk of 1:40 for men and 1:110 for women; the ten year survival rates are only approx. 50%. The treatments are limited: giving chemotherapy prior to surgery or radiotherapy or combining it with radiotherapy can help these treatments, but the main issue facing clinicians is that currently there is no marker available to predict which patients will respond to chemotherapy and consequently which patients will go on to develop metastatic disease. If such a marker were identified then patients who will not benefit from chemotherapy could be offered surgery or radiotherapy immediately, avoiding delay and reducing the time available for the tumour to progress further. The insulin-like growth factor axis is important in the growth, survival and progression of bladder cancer. One of these, IGFBP-2, is a potential biomarker that we have identified from cancer cell line studies as a marker of chemo-sensitivity and of progression. We wish to investigate the role of IGFBP-2 further in human tissue and to also assess the role of other members and associated members of the IGF family together with markers of disease progression.
REC name
London - Queen Square Research Ethics Committee
REC reference
15/LO/2143
Date of REC Opinion
3 Dec 2015
REC opinion
Favourable Opinion